Physician profile
Robert H Chu
NPI 1811997117
$12,829.24
in general payments reported to CMS, 2019-2025
37 companies · $1,887 in 2025
The $1,887 reported for 2025 was more than what 88% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,203 · 2020: $963 · 2021: $1,777 · 2022: $1,773 · 2023: $3,219 · 2024: $2,007 · 2025: $1,887.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,087 · Honoraria: $25.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,087.40 |
| Honoraria | $25.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $2,891.27 | 2020-2025 | Acthar |
| Allergan, INC. | $1,397.01 | 2019-2022 | |
| Sun Pharmaceutical Industries INC. | $1,121.16 | 2019-2025 | Cequa |
| Alcon Vision LLC | $915.37 | 2019-2025 | Rocklatan, Clareon, Eysuvis |
| Abbvie INC. | $777.08 | 2019-2025 | Lumigan, Alphagan P, Durysta |
| Lensar, INC. | $714.78 | 2023 | Lensar Laser System |
| Oyster Point Pharma, INC. | $444.27 | 2022-2025 | Tyrvaya, Ryzumvi |
| Tarsus Pharmaceuticals, INC. | $416.34 | 2024-2025 | Xdemvy |
| Ani Pharmaceuticals, INC. | $352.63 | 2022-2025 | Purified Cortrophin Gel, Iluvien |
| New World Medical,INC. | $332.50 | 2023 | |
| Bausch & Lomb Americas INC. | $291.93 | 2022-2025 | Miebo, Vyzulta, Xiidra |
| Johnson & Johnson Surgical Vision, INC. | $288.30 | 2019-2022 | |
| Amgen INC. | $265.50 | 2024-2025 | Tepezza |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $228.42 | 2019-2021 | |
| Johnson & Johnson Vision Care, INC. | $216.46 | 2019-2025 | Acuvue |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harrow Eye, LLC | $209.75 | 2024-2025 | Vevye |
| Alcon Research LLC | $184.95 | 2021 | |
| Biotissue Holdings INC. | $183.53 | 2022-2025 | |
| Rxsight INC | $173.46 | 2022-2025 | Rxsight Injector Cartridge, Rxsight Contact Lens, Rxsight Injector Handpiece |
| Novartis Pharmaceuticals Corporation | $172.32 | 2019-2023 | |
| Kala Pharmaceuticals, INC. | $169.94 | 2019-2022 | |
| Mallinckrodt Enterprises LLC | $167.13 | 2019 | |
| Dompe US, INC. | $165.65 | 2020-2025 | Oxervate |
| Ivantis, INC | $150.00 | 2019 | |
| Aerie Pharmaceuticals, INC. | $149.89 | 2019-2021 | |
| Glaukos Corporation | $80.55 | 2025 | Idosetr |
| Horizon Therapeutics Plc | $69.26 | 2022-2023 | Tepezza |
| Thea Pharma INC. | $66.83 | 2022-2024 | Iyuzeh |
| Sight Sciences, INC. | $61.66 | 2019-2022 | |
| Tearlab Corp | $38.23 | 2024 | Scoutpro Osmolarity System |
| Eyevance Pharmaceuticals LLC | $30.54 | 2019-2020 | |
| Shire North American Group INC | $21.17 | 2019 | |
| Spark Therapeutics, INC. | $19.03 | 2021 | |
| Coopervision INC. | $16.35 | 2024 | Myday Contact Lens |
| Astellas Pharma US INC | $16.18 | 2024 | Izervay |
| Omeros Corporation | $16.04 | 2019 | |
| Plexus Optix, INC. | $13.76 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Chu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.